

# Sapna P Patel

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7821939/publications.pdf>

Version: 2024-02-01

90  
papers

11,168  
citations

126907

33  
h-index

69250

77  
g-index

97  
all docs

97  
docs citations

97  
times ranked

16816  
citing authors

#	ARTICLE	IF	CITATIONS
1	Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti-CTLA4 and anti-PD1 combination immunotherapy: Incidence, management, and clinical benefit. <i>Cancer</i> , 2022, 128, 975-983.	4.1	12
2	Adjuvant Pembrolizumab versus IFN-2b or Ipilimumab in Resected High-Risk Melanoma. <i>Cancer Discovery</i> , 2022, 12, 644-653.	9.4	32
3	25 Years of Adjuvant Therapy in Melanoma: A Perspective on Current Approvals and Insights into Future Directions. <i>Current Oncology Reports</i> , 2022, 24, 533-542.	4.0	3
4	The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling. , 2022, 10, e003533.		7
5	Second Primary Malignancies in Patients With Melanoma Subtypes: Analysis of 120,299 Patients From the SEER Database (2000-2016). <i>Frontiers in Oncology</i> , 2022, 12, 853076.	2.8	2
6	Case Report: Neuromyelitis Optica After Treatment of Uveal Melanoma With Nivolumab and Ipilimumab. <i>Frontiers in Oncology</i> , 2022, 12, 806501.	2.8	10
7	Distinct molecular and immune hallmarks of inflammatory arthritis induced by immune checkpoint inhibitors for cancer therapy. <i>Nature Communications</i> , 2022, 13, 1970.	12.8	34
8	Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. <i>Clinical Cancer Research</i> , 2022, 28, 1911-1924.	7.0	3
9	Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy. <i>Nature</i> , 2022, 606, 797-803.	27.8	54
10	The Latest on Uveal Melanoma Research and Clinical Trials: Updates from the Cure Ocular Melanoma (CURE OM) Science Meeting (2019). <i>Clinical Cancer Research</i> , 2021, 27, 28-33.	7.0	19
11	Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis. <i>British Journal of Cancer</i> , 2021, 124, 574-580.	6.4	27
12	Dose-escalation study of vemurafenib with sorafenib or crizotinib in patients with BRAF-mutated advanced cancers. <i>Cancer</i> , 2021, 127, 391-402.	4.1	6
13	Nivolumab and Ipilimumab in Metastatic Uveal Melanoma: Results From a Single-Arm Phase II Study. <i>Journal of Clinical Oncology</i> , 2021, 39, 599-607.	1.6	156
14	Influence of injection technique, drug formulation and tumor microenvironment on intratumoral immunotherapy delivery and efficacy. , 2021, 9, e001800.		59
15	The efficacy of anti-programmed cell death protein 1 therapy among patients with metastatic acral and metastatic mucosal melanoma. <i>Cancer Medicine</i> , 2021, 10, 2293-2299.	2.8	15
16	Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. , 2021, 9, e002449.		16
17	Immunotherapy combined with high- and low-dose radiation to all sites leads to complete clearance of disease in a patient with metastatic vaginal melanoma. <i>Gynecologic Oncology</i> , 2021, 161, 645-652.	1.4	15
18	Metastatic Risk Factors Associated with Class 1A Uveal Melanoma Patients. <i>Cancers</i> , 2021, 13, 3292.	3.7	4

#	ARTICLE	IF	CITATIONS
19	Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockade. <i>Nature Medicine</i> , 2021, 27, 1432-1441.	30.7	216
20	Phase I/II trial of a long peptide vaccine (LPV7) plus toll-like receptor (TLR) agonists with or without incomplete Freund's adjuvant (IFA) for resected high-risk melanoma. , 2021, 9, e003220.		20
21	An Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients with Metastatic Melanoma. <i>Oncimmunology</i> , 2021, 10, 1984059.	4.6	2
22	Dietary fiber and probiotics influence the gut microbiome and melanoma immunotherapy response. <i>Science</i> , 2021, 374, 1632-1640.	12.6	369
23	Intracranial antitumor activity with encorafenib plus binimetinib in patients with melanoma brain metastases: A case series. <i>Cancer</i> , 2020, 126, 523-530.	4.1	43
24	A Phase Ib/II Study of the BRAF Inhibitor Encorafenib Plus the MEK Inhibitor Binimetinib in Patients with BRAFV600E/K</i>-mutant Solid Tumors. <i>Clinical Cancer Research</i> , 2020, 26, 5102-5112.	7.0	23
25	Immune profiling of uveal melanoma identifies a potential signature associated with response to immunotherapy. , 2020, 8, e000960.		31
26	A phase II study of the insulin-like growth factor type I receptor inhibitor IMC-A12 in patients with metastatic uveal melanoma. <i>Melanoma Research</i> , 2020, 30, 574-579.	1.2	12
27	Assessment of Image-Guided Intratumoral Delivery of Immunotherapeutics in Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e207911.	5.9	59
28	A Phase II Study of Glematumumab Vedotin for Metastatic Uveal Melanoma. <i>Cancers</i> , 2020, 12, 2270.	3.7	18
29	Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy†. <i>Annals of Oncology</i> , 2020, 31, 1075-1082.	1.2	62
30	Calcium-sensing receptor autoantibody-mediated hypoparathyroidism associated with immune checkpoint inhibitor therapy: diagnosis and long-term follow-up. , 2020, 8, e000687.		21
31	B cells and tertiary lymphoid structures promote immunotherapy response. <i>Nature</i> , 2020, 577, 549-555.	27.8	1,421
32	Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III Melanoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1429-1441.	1.6	23
33	Systemic Therapy for Mucosal, Acral, and Uveal Melanoma. , 2020, , 1301-1335.		2
34	311...Phase II trial of lymphodepletion plus adoptive cell transfer with or without dendritic cell vaccination in patients with metastatic melanoma. , 2020, , .		1
35	Circulating Tumor Cells and Early Relapse in Node-positive Melanoma. <i>Clinical Cancer Research</i> , 2020, 26, 1886-1895.	7.0	42
36	Incidence, patterns of progression, and outcomes of preexisting and newly discovered brain metastases during treatment with anti-PD-1 in patients with metastatic melanoma. <i>Cancer</i> , 2019, 125, 4193-4202.	4.1	9

#	ARTICLE	IF	CITATIONS
37	Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 553-561.	4.2	57
38	Pilot Study of Circulating Tumor Cells in Early-Stage and Metastatic Uveal Melanoma. <i>Cancers</i> , 2019, 11, 856.	3.7	31
39	Meta-analysis in metastatic uveal melanoma to determine progression free and overall survival benchmarks: an international rare cancers initiative (IRC) ocular melanoma study. <i>Annals of Oncology</i> , 2019, 30, 1370-1380.	1.2	171
40	Adjuvant Ipilimumab in High-Risk Uveal Melanoma. <i>Cancers</i> , 2019, 11, 152.	3.7	27
41	Therapy with high-dose Interleukin-2 (HD IL-2) in metastatic melanoma and renal cell carcinoma following PD1 or PDL1 inhibition. , 2019, 7, 49.		102
42	First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6309-6319.	7.0	114
43	Phase 1 study of the combination of vemurafenib, carboplatin, and paclitaxel in patients with BRAF $\mu$ mutated melanoma and other advanced malignancies. <i>Cancer</i> , 2019, 125, 463-472.	4.1	10
44	Systemic Therapy for Mucosal, Acral and Uveal Melanoma. , 2019, , 1-37.		1
45	Regressed melanocytic nevi secondary to pembrolizumab therapy: an emerging melanocytic dermatologic effect from immune checkpoint antibody blockade. <i>International Journal of Dermatology</i> , 2019, 58, 1045-1052.	1.0	11
46	Abstract 2838: The gut microbiome (GM) and immunotherapy response are influenced by host lifestyle factors. <i>Cancer Research</i> , 2019, 79, 2838-2838.	0.9	50
47	Abstract 1493: Therapeutic efficacy and tolerability of combined immune checkpoint blockade in metastatic melanoma patients is influenced by the gut microbiome. <i>Cancer Research</i> , 2019, 79, 1493-1493.	0.9	3
48	Phase I/II Study of Hepatic Arterial Infusion of Nab-paclitaxel in Patients With Metastatic Melanoma to the Liver. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2018, 41, 1132-1136.	1.3	5
49	Obstacles to improving outcomes in the treatment of uveal melanoma. <i>Cancer</i> , 2018, 124, 2693-2703.	4.1	15
50	Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. <i>ESMO Open</i> , 2018, 3, e000283.	4.5	45
51	Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. <i>Lancet Oncology</i> , The, 2018, 19, 181-193.	10.7	233
52	First-in-Class ERK1/2 Inhibitor Ulixertinib (BVD-523) in Patients with MAPK Mutant Advanced Solid Tumors: Results of a Phase I Dose-Escalation and Expansion Study. <i>Cancer Discovery</i> , 2018, 8, 184-195.	9.4	283
53	Gut microbiome modulates response to anti- $\mu$ PD-1 immunotherapy in melanoma patients. <i>Science</i> , 2018, 359, 97-103.	12.6	3,126
54	Long-Term Outcomes in Patients With <i>BRAF</i> V600 $\mu$ Mutant Metastatic Melanoma Who Received Dabrafenib Combined With Trametinib. <i>Journal of Clinical Oncology</i> , 2018, 36, 667-673.	1.6	196

#	ARTICLE	IF	CITATIONS
55	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. <i>Nature Medicine</i> , 2018, 24, 1649-1654.	30.7	592
56	Association between melanoma and renal-cell carcinoma for sequential diagnoses: A single-center retrospective study. <i>Cancer Epidemiology</i> , 2018, 57, 80-84.	1.9	7
57	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. , 2018, 6, 103.		130
58	Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical Outcome. <i>Clinical Cancer Research</i> , 2018, 24, 4416-4428.	7.0	89
59	Utilizing T-cell Activation Signals 1, 2, and 3 for Tumor-infiltrating Lymphocytes (TIL) Expansion: The Advantage Over the Sole Use of Interleukin-2 in Cutaneous and Uveal Melanoma. <i>Journal of Immunotherapy</i> , 2018, 41, 399-405.	2.4	32
60	Leptomeningeal disease in uveal melanoma: a case series. <i>Journal of Neuro-Oncology</i> , 2018, 139, 503-505.	2.9	2
61	Circulating Tumor Cells in Stage IV Melanoma Patients. <i>Journal of the American College of Surgeons</i> , 2018, 227, 116-124.	0.5	17
62	Case Report of Myeloid Sarcoma Masquerading as In-Transit Metastasis at a Previous Melanoma Site: Avoiding a Diagnostic Pitfall. <i>American Journal of Dermatopathology</i> , 2018, 40, 831-835.	0.6	1
63	Abstract 614: Resiquimod, a Toll-like receptor agonist promotes melanoma regression by enhancing plasmacytoid dendritic cells and T cytotoxic activity as a vaccination adjuvant and by direct tumor application. <i>Cancer Research</i> , 2018, 78, 614-614.	0.9	5
64	Abstract 5711: The impact of combination oral azacitidine (CC-486) + pembrolizumab (PEMBRO) on the immune infiltrate in metastatic melanoma (MM). , 2018, , .		0
65	Abstract 3640: Treatment strategies using anti-PD1/PD-L1 (anti-PD) and BRAF/MEK inhibitor (BRAFi) therapy: a retrospective study comparing sequential vs. concurrent administration in BRAF-mutated metastatic melanoma (BMMM). , 2018, , .		0
66	Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistance. <i>Science Translational Medicine</i> , 2017, 9, .	12.4	689
67	A phase II study of ipilimumab plus temozolomide in patients with metastatic melanoma. <i>Cancer Immunology, Immunotherapy</i> , 2017, 66, 1359-1366.	4.2	29
68	Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. <i>Npj Genomic Medicine</i> , 2017, 2, .	3.8	120
69	Impact of Sequencing Targeted Therapies With High-dose Interleukin-2 Immunotherapy: An Analysis of Outcome and Survival of Patients With Metastatic Renal Cell Carcinoma From an On-going Observational IL-2 Clinical Trial: PROCLAIM SM. <i>Clinical Genitourinary Cancer</i> , 2017, 15, 31-41.e4.	1.9	31
70	Parallel profiling of immune infiltrate subsets in uveal melanoma versus cutaneous melanoma unveils similarities and differences: A pilot study. <i>Onc Immunology</i> , 2017, 6, e1321187.	4.6	45
71	Comparative analysis of the <i>GNAQ</i> , <i>GNA11</i> , <i>SF3B1</i> , and <i>EIF1AX</i> driver mutations in melanoma and across the cancer spectrum. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 470-473.	3.3	18
72	Uveal melanoma: From diagnosis to treatment and the science in between. <i>Cancer</i> , 2016, 122, 2299-2312.	4.1	272

#	ARTICLE	IF	CITATIONS
73	Immunotherapy for uveal melanoma. <i>Melanoma Management</i> , 2016, 3, 125-135.	0.5	3
74	Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Resistant Refractory Metastatic Melanoma. <i>JAMA Oncology</i> , 2016, 2, 1056.	7.1	41
75	A retrospective analysis of High-Dose Interleukin-2 (HD IL-2) following Ipilimumab in metastatic melanoma. <i>Journal of Clinical Oncology</i> , 2016, 4, 52.		37
76	BRAF Mutation Testing in Cell-Free DNA from the Plasma of Patients with Advanced Cancers Using a Rapid, Automated Molecular Diagnostics System. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 1397-1404.	4.1	78
77	GNA11 Mutation in a Patient With Cutaneous Origin Melanoma. <i>Medicine (United States)</i> , 2016, 95, e2336.	1.0	9
78	Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade. <i>Cancer Discovery</i> , 2016, 6, 827-837.	9.4	785
79	Distinct clinical patterns and immune infiltrates are observed at time of progression on targeted therapy versus immune checkpoint blockade for melanoma. <i>Oncimmunology</i> , 2016, 5, e1136044.	4.6	55
80	Intrathecal Administration of Tumor-Infiltrating Lymphocytes Is Well Tolerated in a Patient with Leptomeningeal Disease from Metastatic Melanoma: A Case Report. <i>Cancer Immunology Research</i> , 2015, 3, 1201-1206.	3.4	29
81	Beyond BRAF V600 : Clinical Mutation Panel Testing by Next-Generation Sequencing in Advanced Melanoma. <i>Journal of Investigative Dermatology</i> , 2015, 135, 508-515.	0.7	138
82	BRAF mutation testing with a rapid, fully integrated molecular diagnostics system. <i>Oncotarget</i> , 2015, 6, 26886-26894.	1.8	45
83	GNAQ mutation in a patient with metastatic mucosal melanoma. <i>BMC Cancer</i> , 2014, 14, 516.	2.6	18
84	It's Not Always Right, Left is Rare. <i>Annals of Thoracic Surgery</i> , 2014, 97, 1482-1483.	1.3	0
85	Latest Developments in the Biology and Management of Uveal Melanoma. <i>Current Oncology Reports</i> , 2013, 15, 509-516.	4.0	25
86	Clinical responses to selumetinib (AZD6244;ARRY-42886)-based combination therapy stratified by gene mutations in patients with metastatic melanoma. <i>Cancer</i> , 2013, 119, 799-805.	4.1	63
87	Surveillance Options for Patients with Uveal Melanoma Following Definitive Management. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2013, 33, 382-387.	3.8	16
88	Specific Lymphocyte Subsets Predict Response to Adoptive Cell Therapy Using Expanded Autologous Tumor-Infiltrating Lymphocytes in Metastatic Melanoma Patients. <i>Clinical Cancer Research</i> , 2012, 18, 6758-6770.	7.0	345
89	Profile of ipilimumab and its role in the treatment of metastatic melanoma. <i>Drug Design, Development and Therapy</i> , 2011, 5, 489.	4.3	23
90	A phase II study of gefitinib in patients with metastatic melanoma. <i>Melanoma Research</i> , 2011, 21, 357-363.	1.2	33